Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07457671Phase 2Not Yet Recruiting

TAR-0520 Gel in Hand and Foot Syndrome

Role: lead

NCT07082764Phase 2Not Yet Recruiting

Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

Role: lead

NCT06818058Phase 2Recruiting

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

Role: lead

All 3 trials loaded